Synthesis, antifungal activity and antibacterial evaluation of some 3-piperazinylmethyl-5-aryl-1H-1,2,4-triazoles. 1998

S S Papakonstantinou-Garoufalias, and O G Todoulou, and E C Filippatos, and A E Papadaki-Valiraki, and A Chytiroglou-Lada
Department of Pharmacy, School of Medicine, University of Athens, Greece.

Some new 3-piperazinylmethyl-5-aryl-1H-1,2,4-triazoles have been prepared and tested for their antifungal and antimicrobial activity. Among them, compounds 3g and 3h exhibited higher antifungal activity than ketoconazole against Cladosporium cladosporoides and Aspergillus niger respectively.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D005658 Fungi A kingdom of eukaryotic, heterotrophic organisms that live parasitically as saprobes, including MUSHROOMS; YEASTS; smuts, molds, etc. They reproduce either sexually or asexually, and have life cycles that range from simple to complex. Filamentous fungi, commonly known as molds, refer to those that grow as multicellular colonies. Fungi, Filamentous,Molds,Filamentous Fungi,Filamentous Fungus,Fungus,Fungus, Filamentous,Mold
D000890 Anti-Infective Agents Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. Anti-Infective Agent,Anti-Microbial Agent,Antimicrobial Agent,Microbicide,Microbicides,Anti-Microbial Agents,Antiinfective Agents,Antimicrobial Agents,Agent, Anti-Infective,Agent, Anti-Microbial,Agent, Antimicrobial,Agents, Anti-Infective,Agents, Anti-Microbial,Agents, Antiinfective,Agents, Antimicrobial,Anti Infective Agent,Anti Infective Agents,Anti Microbial Agent,Anti Microbial Agents
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D000935 Antifungal Agents Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. Anti-Fungal Agents,Antifungal Agent,Fungicides, Therapeutic,Antibiotics, Antifungal,Therapeutic Fungicides,Agent, Antifungal,Anti Fungal Agents,Antifungal Antibiotics
D001419 Bacteria One of the three domains of life (the others being Eukarya and ARCHAEA), also called Eubacteria. They are unicellular prokaryotic microorganisms which generally possess rigid cell walls, multiply by cell division, and exhibit three principal forms: round or coccal, rodlike or bacillary, and spiral or spirochetal. Bacteria can be classified by their response to OXYGEN: aerobic, anaerobic, or facultatively anaerobic; by the mode by which they obtain their energy: chemotrophy (via chemical reaction) or PHOTOTROPHY (via light reaction); for chemotrophs by their source of chemical energy: CHEMOLITHOTROPHY (from inorganic compounds) or chemoorganotrophy (from organic compounds); and by their source for CARBON; NITROGEN; etc.; HETEROTROPHY (from organic sources) or AUTOTROPHY (from CARBON DIOXIDE). They can also be classified by whether or not they stain (based on the structure of their CELL WALLS) with CRYSTAL VIOLET dye: gram-negative or gram-positive. Eubacteria
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014230 Triazoles Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3. Triazole
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

S S Papakonstantinou-Garoufalias, and O G Todoulou, and E C Filippatos, and A E Papadaki-Valiraki, and A Chytiroglou-Lada
November 2008, Archiv der Pharmazie,
S S Papakonstantinou-Garoufalias, and O G Todoulou, and E C Filippatos, and A E Papadaki-Valiraki, and A Chytiroglou-Lada
November 1976, Chemical & pharmaceutical bulletin,
S S Papakonstantinou-Garoufalias, and O G Todoulou, and E C Filippatos, and A E Papadaki-Valiraki, and A Chytiroglou-Lada
January 2002, Arzneimittel-Forschung,
S S Papakonstantinou-Garoufalias, and O G Todoulou, and E C Filippatos, and A E Papadaki-Valiraki, and A Chytiroglou-Lada
December 2017, Chemical biology & drug design,
S S Papakonstantinou-Garoufalias, and O G Todoulou, and E C Filippatos, and A E Papadaki-Valiraki, and A Chytiroglou-Lada
March 1978, Chemical & pharmaceutical bulletin,
S S Papakonstantinou-Garoufalias, and O G Todoulou, and E C Filippatos, and A E Papadaki-Valiraki, and A Chytiroglou-Lada
October 1971, Journal of medicinal chemistry,
S S Papakonstantinou-Garoufalias, and O G Todoulou, and E C Filippatos, and A E Papadaki-Valiraki, and A Chytiroglou-Lada
January 1983, Acta pharmaceutica Suecica,
S S Papakonstantinou-Garoufalias, and O G Todoulou, and E C Filippatos, and A E Papadaki-Valiraki, and A Chytiroglou-Lada
January 1987, Acta pharmaceutica Suecica,
S S Papakonstantinou-Garoufalias, and O G Todoulou, and E C Filippatos, and A E Papadaki-Valiraki, and A Chytiroglou-Lada
January 2017, The Journal of organic chemistry,
S S Papakonstantinou-Garoufalias, and O G Todoulou, and E C Filippatos, and A E Papadaki-Valiraki, and A Chytiroglou-Lada
January 1989, Annales pharmaceutiques francaises,
Copied contents to your clipboard!